Kyverna Therapeutics (NASDAQ:KYTX) Cut to “Sell” at Wall Street Zen

Wall Street Zen cut shares of Kyverna Therapeutics (NASDAQ:KYTX) from a hold rating to a sell rating in a report released on Saturday.

KYTX has been the subject of several other research reports. Morgan Stanley set a $33.00 price target on Kyverna Therapeutics in a research note on Monday, December 15th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Kyverna Therapeutics in a report on Monday, December 29th. Finally, Wells Fargo & Company upped their target price on Kyverna Therapeutics from $31.00 to $33.00 and gave the company an “overweight” rating in a report on Tuesday, December 16th. Four research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Kyverna Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $28.67.

Kyverna Therapeutics Stock Down 0.6%

Shares of NASDAQ:KYTX opened at $7.89 on Friday. The firm has a market cap of $345.58 million, a P/E ratio of -2.12 and a beta of 3.31. Kyverna Therapeutics has a 12-month low of $1.78 and a 12-month high of $13.67. The business has a fifty day simple moving average of $8.36 and a 200 day simple moving average of $7.52.

Hedge Funds Weigh In On Kyverna Therapeutics

A number of large investors have recently modified their holdings of KYTX. Public Employees Retirement System of Ohio acquired a new stake in Kyverna Therapeutics in the 3rd quarter valued at $28,000. Capital Advisors Inc. OK bought a new stake in shares of Kyverna Therapeutics during the third quarter worth about $60,000. EntryPoint Capital LLC acquired a new stake in shares of Kyverna Therapeutics in the 4th quarter worth about $94,000. Catalyst Funds Management Pty Ltd bought a new position in Kyverna Therapeutics in the 2nd quarter valued at about $37,000. Finally, Phoenix Wealth Advisors boosted its stake in Kyverna Therapeutics by 17.1% during the 4th quarter. Phoenix Wealth Advisors now owns 12,300 shares of the company’s stock valued at $116,000 after purchasing an additional 1,800 shares during the last quarter. 18.08% of the stock is currently owned by institutional investors.

Kyverna Therapeutics Company Profile

Kyverna Therapeutics is a clinical‐stage biotechnology company dedicated to developing engineered regulatory T‐cell (Treg) therapies for the treatment of autoimmune and inflammatory diseases. Leveraging a proprietary platform for the isolation, expansion and modification of Treg cells, the company aims to restore immune homeostasis in patients by delivering antigen‐specific cell therapies that selectively target diseased tissues while minimizing systemic immunosuppression.

The company’s lead programs include an allogeneic Treg candidate in clinical development for ulcerative colitis, with additional preclinical assets focused on rheumatoid arthritis and other chronic inflammatory conditions.